Sanford C. Bernstein Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price decreased by investment analysts at Sanford C. Bernstein from $314.00 to $310.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s target price would indicate a potential upside of 28.87% from the company’s current price.

A number of other research firms also recently issued reports on ALNY. TD Cowen raised their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Raymond James increased their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Finally, Bank of America increased their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Trading Up 1.9 %

NASDAQ:ALNY opened at $240.55 on Tuesday. The stock’s 50 day moving average price is $250.12 and its 200 day moving average price is $259.54. The company has a market capitalization of $31.03 billion, a PE ratio of -91.81 and a beta of 0.34. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The firm’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.15 EPS. On average, research analysts anticipate that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,122 shares of company stock valued at $2,540,455. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Fulton Bank N.A. increased its position in Alnylam Pharmaceuticals by 28.9% during the fourth quarter. Fulton Bank N.A. now owns 1,343 shares of the biopharmaceutical company’s stock worth $316,000 after buying an additional 301 shares in the last quarter. Nordea Investment Management AB increased its position in Alnylam Pharmaceuticals by 6.7% during the fourth quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company’s stock worth $2,417,000 after buying an additional 637 shares in the last quarter. Everence Capital Management Inc. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth $593,000. Versant Capital Management Inc increased its position in Alnylam Pharmaceuticals by 77.6% during the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 83 shares in the last quarter. Finally, American Trust purchased a new position in Alnylam Pharmaceuticals during the third quarter worth $309,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.